JP2012525426A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012525426A5 JP2012525426A5 JP2012508732A JP2012508732A JP2012525426A5 JP 2012525426 A5 JP2012525426 A5 JP 2012525426A5 JP 2012508732 A JP2012508732 A JP 2012508732A JP 2012508732 A JP2012508732 A JP 2012508732A JP 2012525426 A5 JP2012525426 A5 JP 2012525426A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- depression
- pharmaceutical
- viloxazine
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 239000008177 pharmaceutical agent Substances 0.000 claims 6
- 229960001255 viloxazine Drugs 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 3
- 230000001270 agonistic effect Effects 0.000 claims 2
- 230000003042 antagnostic effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000002474 noradrenergic effect Effects 0.000 claims 2
- 229940076279 serotonin Drugs 0.000 claims 2
- 230000002295 serotoninergic effect Effects 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 241000287463 Phalacrocorax Species 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000003291 dopaminomimetic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- 238000007423 screening assay Methods 0.000 claims 1
- 102000040811 transporter activity Human genes 0.000 claims 1
- 108091092194 transporter activity Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17408409P | 2009-04-30 | 2009-04-30 | |
| US61/174,084 | 2009-04-30 | ||
| PCT/US2010/032974 WO2010127120A1 (en) | 2009-04-30 | 2010-04-29 | Method of treatment of depression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014170572A Division JP2014240417A (ja) | 2009-04-30 | 2014-08-25 | うつ病を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012525426A JP2012525426A (ja) | 2012-10-22 |
| JP2012525426A5 true JP2012525426A5 (https=) | 2013-06-20 |
Family
ID=43032555
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012508732A Pending JP2012525426A (ja) | 2009-04-30 | 2010-04-29 | うつ病を治療する方法 |
| JP2014170572A Pending JP2014240417A (ja) | 2009-04-30 | 2014-08-25 | うつ病を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014170572A Pending JP2014240417A (ja) | 2009-04-30 | 2014-08-25 | うつ病を治療する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20120115871A1 (https=) |
| EP (1) | EP2424539A4 (https=) |
| JP (2) | JP2012525426A (https=) |
| AU (1) | AU2010242971A1 (https=) |
| CA (1) | CA2760527A1 (https=) |
| CO (1) | CO6470848A2 (https=) |
| MX (1) | MX2011011579A (https=) |
| WO (1) | WO2010127120A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2341912B1 (en) | 2008-09-05 | 2014-01-22 | Supernus Pharmaceuticals, Inc. | Method of treatment of attention deficit/hyperactivity disorder (adhd) |
| AU2013217013B2 (en) | 2012-02-08 | 2017-04-20 | Supernus Pharmaceuticals, Inc. | Modified release formulations of viloxazine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4260606A (en) * | 1979-07-19 | 1981-04-07 | A. H. Robins Company, Inc. | 3-Methyleneazetidine derivatives |
| DE19830201A1 (de) * | 1998-07-07 | 2000-01-13 | Boehringer Ingelheim Pharma | Mittel mit antidepressiver Wirkung |
| WO2000006162A1 (de) * | 1998-07-27 | 2000-02-10 | Boehringer Ingelheim Pharma Kg | Mittel mit antidepressiver wirkung, mit pramipexol und einem weiteren antidepressivum |
| JP2004517112A (ja) * | 2001-01-02 | 2004-06-10 | ファルマシア・アンド・アップジョン・カンパニー | 新規薬物コンビネーション |
| AU2007260356B2 (en) * | 2006-06-16 | 2013-01-24 | H. Lundbeck A/S | Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain |
| EP2341912B1 (en) * | 2008-09-05 | 2014-01-22 | Supernus Pharmaceuticals, Inc. | Method of treatment of attention deficit/hyperactivity disorder (adhd) |
-
2010
- 2010-04-29 JP JP2012508732A patent/JP2012525426A/ja active Pending
- 2010-04-29 WO PCT/US2010/032974 patent/WO2010127120A1/en not_active Ceased
- 2010-04-29 CA CA2760527A patent/CA2760527A1/en not_active Abandoned
- 2010-04-29 US US13/318,007 patent/US20120115871A1/en not_active Abandoned
- 2010-04-29 EP EP10770332A patent/EP2424539A4/en not_active Withdrawn
- 2010-04-29 MX MX2011011579A patent/MX2011011579A/es not_active Application Discontinuation
- 2010-04-29 AU AU2010242971A patent/AU2010242971A1/en not_active Abandoned
-
2011
- 2011-11-30 CO CO11165136A patent/CO6470848A2/es not_active Application Discontinuation
-
2014
- 2014-08-25 JP JP2014170572A patent/JP2014240417A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111201039B (zh) | 大麻二酚与5-ht2b受体激动剂安非他明的组合治疗癫痫的用途 | |
| Ghatalia et al. | QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors | |
| Pioro et al. | Dextromethorphan plus ultra low‐dose quinidine reduces pseudobulbar affect | |
| Hu et al. | Single iv ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study | |
| Greist et al. | Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine | |
| Vermoesen et al. | The antidepressants citalopram and reboxetine reduce seizure frequency in rats with chronic epilepsy | |
| JP2017528483A5 (https=) | ||
| Coppola et al. | Current role of rufinamide in the treatment of childhood epilepsy: literature review and treatment guidelines | |
| JP2017503820A5 (https=) | ||
| MA29432B1 (fr) | Antagonistes du recepteur du glucagon, leur preparation et leurs utilisations therapeutiques | |
| Moreira | The efficacy and tolerability of bupropion in the treatment of major depressive disorder | |
| JP2015524816A5 (https=) | ||
| JP5727457B2 (ja) | ２，４，６−トリフルオロ−ｎ−［６−（１−メチル−ピペリジン−４−カルボニル）−ピリジン−２−イル］−ベンズアミドの組成物 | |
| Miranda et al. | Antinociceptive synergism of gabapentin and nortriptyline in mice with partial sciatic nerve ligation | |
| FI3352735T3 (fi) | Pitkitetysti vapauttavia olantsapiiniformulaatioita | |
| Laurencin et al. | Initial treatment of Parkinson's disease in 2016: The 2000 consensus conference revisited | |
| Buck et al. | L-DOPA-induced dyskinesia in Parkinson's disease: a drug discovery perspective | |
| JP2012525426A5 (https=) | ||
| Ciccone | Geriatric pharmacology | |
| AU2006231752B2 (en) | Preventive or remedy for depression or anxiety neurosis | |
| Kishimoto et al. | The opposite effects of fluvoxamine and sertraline in the treatment of psychotic major depression: a case report | |
| Tsai | Sipatrigine could have therapeutic potential for major depression and bipolar depression through antagonism of the two-pore-domain K+ channel TREK-1 | |
| Andrade | Drug interactions in the treatment of depression in patients receiving β-blocker drugs | |
| Scott | Levomilnacipran extended-release: a review of its use in adult patients with major depressive disorder | |
| Álvarez et al. | Mirtazapine in combination |